Fulgent Genetics, Inc. (FLGT) Balance Sheet

The erosion in equity, primarily through a $144.1M reduction in retained earnings over the last ten quarters, signals that the business is no longer self-funding its operations and is drawing down its historical profit reserves. This trajectory, if it continues, will gradually erode the company's financial cushion and may eventually necessitate external financing or strategic pivots.

The current ratio remains strong at 6.34, but this is misleading as it is heavily supported by non-cash assets. The rapid depletion of the cash balance, which now represents only 2.4% of total assets, suggests the company's ability to absorb further operational losses or make strategic investments without tapping capital markets is becoming severely constrained.

This sustained drawdown of retained earnings is a critical red flag, as it indicates the company is funding its losses by consuming its accumulated profits rather than through debt or equity issuance. The trend suggests the core business model is currently value-destructive, and without a return to profitability, the equity base will continue to erode.

The significant increase in goodwill, while PPE has grown modestly, suggests the company is pursuing growth through acquisition rather than organic investment. This shift in asset composition increases intangible risk, as future impairment charges could further pressure the equity base if the acquired assets do not generate expected returns.